No market is immune to change, and life sciences continues to face its fair share of upheaval as the industry accommodates emerging innovation in healthcare and a raft of other challenges to the status quo. Below are five of the most prominent trends and what they mean in practice.
As a shortcut to attractive new product lines, when development and testing cycles can be frustratingly long, companies are increasingly sizing up strategic purchases. 2016 saw high levels of merger and acquisition (M&A) activity and more of the same had been forecast for 2017 (1,2). Though this has not quite materialised so far, it is expected to pick up in the second half of the year.
However, profiting from these deals means the acquiring company must be able to align its branding, content and labelling quickly, reliably and efficiently. This is essential in upholding brand image, stabilising compliance efforts and maximising process efficiency, as well as market opportunity.
Harnessing automated content checking using technology that can compare and accurately spot and highlight anomalies – at high-speed across huge batches of content assets – can reduce the time taken to verify output by as much as 85%. This can have a marked impact on speed to market for products under new ownership.
This article has been published in the European Biopharmaceutical Review, October 2017